LegoChem Biosciences (LCB) has entered an exclusive worldwide licensing agreement with Glycotope to develop an antibody-drug conjugate (ADC).

Building on the collaboration and licence deal the two companies signed in 2022, this latest agreement will bring together LCB’s ADC technology and one of Glycotope’s investigational antibodies.

Financial terms of the transaction have not been disclosed.

LCB will gain global exclusive rights to develop and commercialise the selected antibody as an ADC.

LCB will make an upfront payment to Glycotope, which is then entitled to receive clinical, regulatory, sales and milestone payments, and royalties on net sales worldwide.

The antibodies developed by Glycotope target particular tumour-linked carbohydrate structures or protein/carbohydrate combined glyco-epitopes (GlycoTargets).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Glycotope chief scientific officer Patrik Kehler stated: “We believe this antibody has excellent potential for the treatment of several solid tumour indications with high medical need.

“The continued progress of our collaboration with LCB, a leading developer of next-generation therapeutics, further highlights the importance of tumour-associated glycosylation in the treatment of cancer and underlines the strengths of our technology.”

Compared to existing technologies, LCB’s ADC platform technologies showcase site-specific stable bioconjugation, cancer-selective linker activation and cancer-selective activation of potent payload.

LegoChem Biosciences CEO and president Dr Yong-Zu Kim stated: “With the licensing of the antibody for the development as an ADC, we are further expanding the number of ADCs we have under development, which demonstrates our commitment to maximising the value of our ADC payload and linker technology.

“We look forward to advancing the programme to clinical stage.”